Advertisement

Child's Nervous System

, Volume 34, Issue 3, pp 395–400 | Cite as

Vagal nerve stimulation for medically refractory epilepsy in Angelman syndrome: a series of three cases

  • Krystal L. Tomei
  • Christine Y. Mau
  • Michael Ghali
  • Jayoung Pak
  • Ira M. Goldstein
Review Paper

Abstract

Background

We describe three children with Angelman syndrome and medically refractory epilepsy.

Methods

Case series of three pediatric patients with Angelman syndrome and medically refractory epilepsy. All three patients failed medical treatment and were recommended for vagal nerve stimulator (VNS) implantation.

Results

Following VNS implantation, all three patients experienced reduction in seizure frequency greater than that afforded by medication alone.

Conclusion

We present vagal nerve stimulator implantation as a viable treatment option for medically refractory epilepsy associated with Angelman syndrome.

Keywords

Vagal nerve stimulation Angelman syndrome Medically refractory epilepsy 

Notes

Compliance with ethical standards

Disclaimer

VNS is currently FDA approved for individuals greater than 12 years of age and all patients in this series were under 12.

Conflict of interest

The authors report no conflict of interest concerning the materials or methods used in this study or the findings specified in this paper.

References

  1. 1.
    Benifla M, Rutka JT, Logan W, Donner EJ (2006) Vagal nerve stimulation for refractory epilepsy in children: indications and experience at The Hospital for Sick Children. Childs Nerv Syst 22(8):1018–1026.  https://doi.org/10.1007/s00381-006-0123-6 CrossRefPubMedGoogle Scholar
  2. 2.
    Bonanni P, Gobbo A, Nappi S, Moret O, Nogarol A, Santin M et al (2009) Functioning and disability in patients with Angelman syndrome: utility of the International Classification of functioning disability and health, children and youth adaptation framework. Disabil Rehabil 31(Suppl 1):S121–S127CrossRefPubMedGoogle Scholar
  3. 3.
    Buiting K (2010) Prader-Willi syndrome and Angelman syndrome. Am J Med Genet C Semin Med Genet 154C(3):365–376.  https://doi.org/10.1002/ajmg.c.30273 CrossRefPubMedGoogle Scholar
  4. 4.
    Buoni S, Grosso S, Pucci L, Fois A (1999) Diagnosis of Angelman syndrome: clinical and EEG criteria. Brain and Development 21(5):296–302.  https://doi.org/10.1016/S0387-7604(99)00007-8 CrossRefPubMedGoogle Scholar
  5. 5.
    Dion MH, Novotny EJ Jr, Carmant L, Cossette P, Nguyen DK (2007) Lamotrigine therapy of epilepsy with Angelman’s syndrome. Epilepsia 48(3):593–596.  https://doi.org/10.1111/j.1528-1167.2006.00969.x CrossRefPubMedGoogle Scholar
  6. 6.
    Dzhala VI, Talos DM, Sdrulla DA, Brumback AC, Mathews GC, Benke TA, Delpire E, Jensen FE, Staley KJ (2005) NKCC1 transporter facilitates seizures in the developing brain. Nat Med 11(11):1205–1213.  https://doi.org/10.1038/nm1301 CrossRefPubMedGoogle Scholar
  7. 7.
    Elia M (2009) Myoclonic status in nonprogressive encephalopathies: an update. Epilepsia 50(Suppl 5):41–44CrossRefPubMedGoogle Scholar
  8. 8.
    Englot DJ, Chang EF, Auguste KI (2011) Vagus nerve stimulation for epilepsy: a meta-analysis of efficacy and predictors of response. J Neurosurg 115(6):1248–1255.  https://doi.org/10.3171/2011.7.JNS11977
  9. 9.
    Fiumara A, Pittala A, Cocuzza M, Sorge G (2010) Epilepsy in patients with Angelman syndrome. Ital J Pediatr 36(1):31.  https://doi.org/10.1186/1824-7288-36-31 CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Forrest KM, Young H, Dale RC, Gill DS (2009) Benefit of corticosteroid therapy in Angelman syndrome. J Child Neurol 24(8):952–958.  https://doi.org/10.1177/0883073808331344 CrossRefPubMedGoogle Scholar
  11. 11.
    Franz DN, Glauser TA, Tudor C, Williams S (2000) Topiramate therapy of epilepsy associated with Angelman’s syndrome. Neurology 54(5):1185–1188.  https://doi.org/10.1212/WNL.54.5.1185 CrossRefPubMedGoogle Scholar
  12. 12.
    Galvan-Manso M, Campistol J, Conill J, Sanmarti FX (2005) Analysis of the characteristics of epilepsy in 37 patients with the molecular diagnosis of Angelman syndrome. Epileptic Disord 7(1):19–25PubMedGoogle Scholar
  13. 13.
    Hammond EJ, Uthman BM, Wilder BJ, Ben-Menachem E, Hamberger A, Hedner T, Ekman R (1992) Neurochemical effects of vagus nerve stimulation in humans. Brain Res 583(1-2):300–303.  https://doi.org/10.1016/S0006-8993(10)80038-1 CrossRefPubMedGoogle Scholar
  14. 14.
    Hassert DL, Miyashita T, Williams CL (2004) The effects of peripheral vagal nerve stimulation at a memory-modulating intensity on norepinephrine output in the basolateral amygdala. Behav Neurosci 118(1):79–88.  https://doi.org/10.1037/0735-7044.118.1.79 CrossRefPubMedGoogle Scholar
  15. 15.
    Helmers SL, Wheless JW, Frost M, Gates J, Levisohn P, Tardo C, Conry JA, Yalnizoglu D, Madsen JR (2001) Vagus nerve stimulation therapy in pediatric patients with refractory epilepsy: retrospective study. J Child Neurol 16(11):843–848.  https://doi.org/10.1177/08830738010160111101 CrossRefPubMedGoogle Scholar
  16. 16.
    Hogart A, Nagarajan RP, Patzel KA, Yasui DH, Lasalle JM (2007) 15q11-13 GABAA receptor genes are normally biallelically expressed in brain yet are subject to epigenetic dysregulation in autism-spectrum disorders. Hum Mol Genet 16(6):691–703.  https://doi.org/10.1093/hmg/ddm014 CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Homanics GE, DeLorey TM, Firestone LL, Quinlan JJ, Handforth A, Harrison NL, Krasowski MD, Rick CEM, Korpi ER, Makela R, Brilliant MH, Hagiwara N, Ferguson C, Snyder K, Olsen RW (1997) Mice devoid of gamma-aminobutyrate type a receptor beta3 subunit have epilepsy, cleft palate, and hypersensitive behavior. Proc Natl Acad Sci U S A 94(8):4143–4148.  https://doi.org/10.1073/pnas.94.8.4143 CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Kyllerman M (1995) On the prevalence of Angelman syndrome. Am J Med Genet 59:405; author reply 403–404CrossRefPubMedGoogle Scholar
  19. 19.
    Laan LA, van Haeringen A, Brouwer OF (1999) Angelman syndrome: a review of clinical and genetic aspects. Clin Neurol Neurosurg 101(3):161–170.  https://doi.org/10.1016/S0303-8467(99)00030-X
  20. 20.
    Laan LA, Vein AA (2005) Angelman syndrome: is there a characteristic EEG? Brain and Development 27(2):80–87.  https://doi.org/10.1016/j.braindev.2003.09.013 CrossRefPubMedGoogle Scholar
  21. 21.
    Landsman IS, Mitzel HM, Peters SU, Bichell TJ (2012) Are children with Angelman syndrome at high risk for anesthetic complications? Paediatr Anaesth 22(3):263–267.  https://doi.org/10.1111/j.1460-9592.2011.03661.x CrossRefPubMedGoogle Scholar
  22. 22.
    Liu Q, Wong-Riley MT (2012) Postnatal development of Na(+)-K(+)-2Cl(−) co-transporter 1 and K(+)-Cl(−) co-transporter 2 immunoreactivity in multiple brain stem respiratory nuclei of the rat. Neuroscience 210:1–20.  https://doi.org/10.1016/j.neuroscience.2012.03.018 CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Minassian BA, DeLorey TM, Olsen RW, Philippart M, Bronstein Y, Zhang Q et al (1998) Angelman syndrome: correlations between epilepsy phenotypes and genotypes. Ann Neurol 43(4):485–493.  https://doi.org/10.1002/ana.410430412 CrossRefPubMedGoogle Scholar
  24. 24.
    Narayanan JT, Watts R, Haddad N, Labar DR, Li PM, Filippi CG (2002) Cerebral activation during vagus nerve stimulation: a functional MR study. Epilepsia 43(12):1509–1514.  https://doi.org/10.1046/j.1528-1157.2002.16102.x CrossRefPubMedGoogle Scholar
  25. 25.
    Paprocka J, Jamroz E, Szwed-Bialozyt B, Jezela-Stanek A, Kopyta I, Marszal E (2007) Angelman syndrome revisited. Neurologist 13(5):305–312.  https://doi.org/10.1097/01.nrl.0000253067.32759.aa CrossRefPubMedGoogle Scholar
  26. 26.
    Patwardhan RV, Stong B, Bebin EM, Mathisen J, Grabb PA (2000) Efficacy of vagal nerve stimulation in children with medically refractory epilepsy. Neurosurgery 47:1353–1357; discussion 1357–1358CrossRefPubMedGoogle Scholar
  27. 27.
    Pelc K, Boyd SG, Cheron G, Dan B (2008) Epilepsy in Angelman syndrome. Seizure 17(3):211–217.  https://doi.org/10.1016/j.seizure.2007.08.004 CrossRefPubMedGoogle Scholar
  28. 28.
    Plotkin MD, Snyder EY, Hebert SC, Delpire E (1997) Expression of the Na-K-2Cl cotransporter is developmentally regulated in postnatal rat brains: a possible mechanism underlying GABA’s excitatory role in immature brain. J Neurobiol 33(6):781–795.  https://doi.org/10.1002/(SICI)1097-4695(19971120)33:6<781::AID-NEU6>3.0.CO;2-5 CrossRefPubMedGoogle Scholar
  29. 29.
    Quinlan JJ, Homanics GE, Firestone LL (1998) Anesthesia sensitivity in mice that lack the beta3 subunit of the gamma-aminobutyric acid type A receptor. Anesthesiology 88(3):775–780.  https://doi.org/10.1097/00000542-199803000-00030 CrossRefPubMedGoogle Scholar
  30. 30.
    Ramanathan KR, Muthuswamy D, Jenkins BJ (2008) Anaesthesia for Angelman syndrome. Anaesthesia 63(6):659–661.  https://doi.org/10.1111/j.1365-2044.2008.05439.x CrossRefPubMedGoogle Scholar
  31. 31.
    Roosevelt RW, Smith DC, Clough RW, Jensen RA, Browning RA (2006) Increased extracellular concentrations of norepinephrine in cortex and hippocampus following vagus nerve stimulation in the rat. Brain Res 1119(1):124–132.  https://doi.org/10.1016/j.brainres.2006.08.048 CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Stein D, Chetty M, Rho JM (2010) A "happy" toddler presenting with sudden, life-threatening seizures. Semin Pediatr Neurol 17(1):35–38.  https://doi.org/10.1016/j.spen.2010.02.002 CrossRefPubMedGoogle Scholar
  33. 33.
    Sugiura C, Ogura K, Ueno M, Toyoshima M, Oka A (2001) High-dose ethosuximide for epilepsy in Angelman syndrome: implication of GABA(A) receptor subunit. Neurology 57(8):1518–1519.  https://doi.org/10.1212/WNL.57.8.1518 CrossRefPubMedGoogle Scholar
  34. 34.
    Tan WH, Bacino CA, Skinner SA, Anselm I, Barbieri-Welge R, Bauer-Carlin A, Beaudet AL, Bichell TJ, Gentile JK, Glaze DG, Horowitz LT, Kothare SV, Lee HS, Nespeca MP, Peters SU, Sahoo T, Sarco D, Waisbren SE, Bird LM (2011) Angelman syndrome: mutations influence features in early childhood. Am J Med Genet A 155A(1):81–90.  https://doi.org/10.1002/ajmg.a.33775 CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Thibert RL, Conant KD, Braun EK, Bruno P, Said RR, Nespeca MP, Thiele EA (2009) Epilepsy in Angelman syndrome: a questionnaire-based assessment of the natural history and current treatment options. Epilepsia 50(11):2369–2376.  https://doi.org/10.1111/j.1528-1167.2009.02108.x CrossRefPubMedGoogle Scholar
  36. 36.
    Thomson AK, Glasson EJ, Bittles AH (2006) A long-term population-based clinical and morbidity profile of Angelman syndrome in Western Australia: 1953-2003. Disabil Rehabil 28(5):299–305.  https://doi.org/10.1080/09638280500190631 CrossRefPubMedGoogle Scholar
  37. 37.
    Uemura N, Matsumoto A, Nakamura M, Watanabe K, Negoro T, Kumagai T, Miura K, Ohki T, Mizuno S, Okumura A, Aso K, Hayakawa F, Kondo Y (2005) Evolution of seizures and electroencephalographical findings in 23 cases of deletion type Angelman syndrome. Brain and Development 27(5):383–388.  https://doi.org/10.1016/j.braindev.2004.01.009 CrossRefPubMedGoogle Scholar
  38. 38.
    Valente KD, Koiffmann CP, Fridman C, Varella M, Kok F, Andrade JQ, Grossmann RM, Marques-Dias MJ (2006) Epilepsy in patients with Angelman syndrome caused by deletion of the chromosome 15q11-13. Arch Neurol 63(1):122–128.  https://doi.org/10.1001/archneur.63.1.122 CrossRefPubMedGoogle Scholar
  39. 39.
    Vanagt WY, Pulles-Heintzberger CF, Vernooy K, Cornelussen RN, Delhaas T (2005) Asystole during outbursts of laughing in a child with Angelman syndrome. Pediatr Cardiol 26(6):866–868.  https://doi.org/10.1007/s00246-005-0985-5 CrossRefPubMedGoogle Scholar
  40. 40.
    Vendrame M, Loddenkemper T, Zarowski M, Gregas M, Shuhaiber H, Sarco DP, Morales A, Nespeca M, Sharpe C, Haas K, Barnes G, Glaze D, Kothare SV (2012) Analysis of EEG patterns and genotypes in patients with Angelman syndrome. Epilepsy Behav 23(3):261–265.  https://doi.org/10.1016/j.yebeh.2011.11.027 CrossRefPubMedGoogle Scholar
  41. 41.
    Wagstaff J, Knoll JH, Fleming J, Kirkness EF, Martin-Gallardo A, Greenberg F, Graham JM Jr, Menninger J, Ward D, Venter JC (1991) Localization of the gene encoding the GABAA receptor beta 3 subunit to the Angelman/Prader-Willi region of human chromosome 15. Am J Hum Genet 49(2):330–337PubMedPubMedCentralGoogle Scholar
  42. 42.
    Wang C, Shimizu-Okabe C, Watanabe K, Okabe A, Matsuzaki H, Ogawa T, Mori N, Fukuda A, Sato K (2002) Developmental changes in KCC1, KCC2, and NKCC1 mRNA expressions in the rat brain. Brain Res Dev Brain Res 139(1):59–66.  https://doi.org/10.1016/S0165-3806(02)00536-9 CrossRefPubMedGoogle Scholar
  43. 43.
    Williams CA (2010) The behavioral phenotype of the Angelman syndrome. Am J Med Genet C Semin Med Genet 154C(4):432–437.  https://doi.org/10.1002/ajmg.c.30278 CrossRefPubMedGoogle Scholar
  44. 44.
    Williams CA (2005) Neurological aspects of the Angelman syndrome. Brain and Development 27(2):88–94.  https://doi.org/10.1016/j.braindev.2003.09.014 CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • Krystal L. Tomei
    • 1
  • Christine Y. Mau
    • 2
  • Michael Ghali
    • 3
  • Jayoung Pak
    • 4
  • Ira M. Goldstein
    • 5
  1. 1.University Hospitals Case Medical CenterRainbow Babies and Children’s HospitalClevelandUSA
  2. 2.Department of Neurological SurgeryPenn State Milton S. Hershey Medical CenterHersheyUSA
  3. 3.Department of General SurgeryPenn State Milton S. Hershey Medical CenterHersheyUSA
  4. 4.Department of NeurologyRutgers New Jersey Medical School NewarkNewarkUSA
  5. 5.Department of Neurological SurgeryRutgers New Jersey Medical SchoolNewarkUSA

Personalised recommendations